Drug – bio-affecting and body treating compositions – Preparations characterized by special physical form
Reexamination Certificate
1998-09-03
2001-11-13
Page, Thurman K. (Department: 1615)
Drug, bio-affecting and body treating compositions
Preparations characterized by special physical form
C424S457000, C424S464000, C424S468000, C424S439000, C424S440000, C424S441000
Reexamination Certificate
active
06316008
ABSTRACT:
FIELD OF INVENTION
This invention relates to zinc compositions for oral use and methods of making. More particularly, this invention relates to compositions containing a combination of a zinc compound (acting as a source of zinc ions) and a source of ascorbic acid (Vitamin C), which when taken orally are palatable and have no undesirable aftertaste. These compositions include, in addition to the zinc compound and the ascorbic acid source, an amino acid, and a base material.
BACKGROUND OF THE INVENTION
The value of nutritional supplements of elemental zinc is well established. Hypogonadism in males, skin changes, poor appetite, and mental lethargy are but some of the observable effects related to zinc deficiency in man. Approximately 100 enzymes, many of them essential to human well-being, have been found to contain zinc, and the evidence is strong that zinc is required for many (if not all) of these enzymes to express their activity. Several enzymes required for nucleic acid metabolism have been shown to require zinc. In this group are ribonucleic acid (RNA) and deoxyribonucleic acid (DNA) polymerases, deoxythymidine kinase, and reverse transcriptase. It has been shown experimentally that the activity of deoxythymidine kinase in rapidly regenerating connective tissue decreases as early as six days after animals are placed on a zinc-deficient diet. This metabolic defect resulting from nutritional zinc deficiency is an indication of the fundamental importance of zinc for cell division and protein synthesis.
Until recently, zinc deficiency in man was considered unlikely because of the widespread availability of zinc in nature. However, recent evidence suggests that nutritional zinc deficiency may be common among the people of many developing countries where they subsist on high cereal protein diets. Only recently has it been recognized that the phytate content of such diets severely restricts zinc availability, which translates nutritionally to markedly depressed zinc absorption in man under many practical circumstances. Marginal zinc deficiency may be widespread even in the United States because of self-imposed dietary restrictions, use of alcohol and cereal proteins, and the increasing use of refined foods which decrease the intake of trace elements. As meat is a major dietary source of zinc, vegetarians who consume cereals as a major source of protein may be in double jeopardy of zinc deficiency.
Therapeutically, zinc has a vital role in certain diseased or debilitated states. Zinc therapy is life saving in acrodermatitis enteropathica, a genetic disease caused by an autosomal recessive trait which, although rare, had an extremely high mortality rate until it was discovered in 1973 that chronic administration of oral zinc salts was not only life saving but capable of lifetime control of the disease. Zinc supplementation markedly improves wound healing in zinc-deficient individuals. Zinc deficiency is an important feature in many cases of sickle cell anemia characterized by growth retardation and hypogonadism, and zinc appears to have a pharmacological anti-sickling effect. Zinc has also been shown to be beneficial in the relief of acute inflammatory conditions associated with rheumatoid arthritis.
It was found by G. A. Eby, D. R. Davis, and W. W. Halcomb as reported in “Reduction in Duration of Common Colds by Zinc Gluconate Lozenges in a Double-Blind Study,”
Antimicrobial Agents and Chemotherapy,
25(1), pp. 20-24 (1984) that when modest quantities of zinc are slowly ingested by mouth so that the interior surfaces of the mouth and throat are intermittently bathed in a solution of ionic zinc, both the time course and the severity of the symptoms of the common cold are remarkably altered in a favorable way. Their double blind clinical study in 65 humans showed that allowing a tablet containing about 23 mg of elemental zinc, such as zinc gluconate, to slowly dissolve in the mouth once every two hours during 12 to 16 hours a day (the waking hours) reduced the duration of colds from 10.8 days in the untreated group to 3.9 days in the zinc-treated group; and at every time after about one day, the zinc-treated patients had a great reduction in cold symptoms compared to the patients who did not receive zinc.
While the reported observations are highly significant both from the point of view of statistical validity and of the importance of these observations to public health, the authors stated repeatedly in their paper that the disagreeable taste of the zinc gluconate tablets was a serious problem. Many patients receiving zinc gluconate discontinued the treatment on the first day “due to objection to the treatment”. The authors stated that “the zinc gluconate lozenges [tablets] we used caused an unexpected unpalatability and distortion of taste in many subjects . . . ” and mentioned “the somewhat bitter aftertaste which some people report for zinc gluconate”. Furthermore, “unpalatable taste,” “distortion of taste,” and “mouth irritation” were common objections.
The original observation of the efficacy of unflavored zinc gluconate tablets has received strong confirmation. Two large, double-blind, placebo-controlled clinical studies have been carried out and reported in the medical literature. The first was carried out at the Dartmouth College Cold Clinic in New Hampshire and reported by J. C. Godfrey, B. Conant Sloane, D. S. Smith, J. H. Turco, N. Mercer, and N. J. Godfrey in “Zinc gluconate and the common cold: A controlled clinical study,”
Journal of International Medical Research,
20(2), pp. 234-246 (1992). This study used sugar-based lozenges containing zinc gluconate equivalent to 23 mg of zinc, and glycine, prepared by serial dilution technology to produce a formulation according to U.S. Pat. No. 4,684,528 and 4,758,439. Participants in this study who met protocol requirements and who received active lozenges within two calendar days of the onset of cold symptoms and dissolved them in their mouths every 2 hours while awake, as specified in the protocol carried out under a U.S. Investigational New Drug Application, experienced colds that lasted only 58% (mean duration) as long as patients who received a placebo. Patients in this study who received the active medication also experienced significant reductions of symptom severity and duration as compared to those who received the placebo.
The second double-blind study was done at the Cleveland Clinic Foundation by S. B. Moussad, M. L. Macknin, S. V. Medendork, and P. Mason and reported in “Zinc Gluconate Lozenges for Treating the Common Cold,”
Annals of Internal Medicine,
125(2), pp. 81-88 (1996). Patients who qualified for this study had cold symptoms for no more than 24 hours prior to entry. The study used zinc gluconate lozenges containing glycine, prepared in the same manner as for the Dartmouth study but containing just 13.3 mg of zinc. When the data from this study were analyzed on the same statistical basis as the Dartmouth study, i.e., using only the 83 out of 100 patients who met all criteria specified in the protocol, it was found that patients who took active medication had colds for only 52% as long as those who got a placebo. As in the Dartmouth study, patients in this study also experienced a rapid reduction in symptom severity, compared to those on a placebo.
As noted, zinc gluconate by itself has a very bad taste. This may be overcome by formulations containing an excess of glycine or certain other selected amino acids making the material palatable enough to be taken with the frequency necessary to suppress symptoms of the common cold.
Vitamin C (ascorbic acid) is established as an important nutrient. In view of the long and generally favorable history of the use of Vitamin C as a dietary supplement, antioxidant, and in the treatment of the common cold, it has become apparent that a combination of a zinc supplement with Vitamin C in a single dose lozenge, or similar type oral dosage form is desirable.
However, until now, all attempts to combine zinc compounds with ascorbic acid or ascorbate salts in a
Breiner & Breiner L.L.C.
Page Thurman K.
Ware Todd D
LandOfFree
Combination of zinc ions and vitamin C and method of making does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Combination of zinc ions and vitamin C and method of making, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Combination of zinc ions and vitamin C and method of making will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2615018